Summary & Overview
HCPCS J3301: Triamcinolone Acetonide Injection, 10 mg
HCPCS Level II code J3301 denotes a 10 mg injection of triamcinolone acetonide, a corticosteroid commonly used for anti-inflammatory and immunosuppressive indications. This drug-supply code is used on medical claims to identify the administered medication unit and is relevant for drug billing, inventory tracking, and payment determinations across outpatient settings. Nationally, accurate use of J3301 matters for claims consistency, drug utilization monitoring, and payer reimbursement processes.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines payer coverage practices and common claim considerations for injectable corticosteroids.
Readers will find a concise clinical context for triamcinolone acetonide injections, typical sites of service where J3301 is billed, and an explanation of which elements drive reimbursement on a national scale. The report provides benchmarks for utilization patterns and payer coverage notes where available, summarizes coding and billing implications for outpatient and office-based administration, and highlights areas where policy updates or payer-specific coverage rules commonly affect claims. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J3301 describes an injection of triamcinolone acetonide, not otherwise specified, 10 mg. This code represents the drug supply for a 10 mg dose of triamcinolone acetonide intended for parenteral administration.
Service Type: Injection (corticosteroid)
Typical Site of Service: Outpatient clinic, physician office, or ambulatory care setting
Clinical & Coding Specifications
Clinical Context
A typical patient is a 54-year-old with focal inflammatory joint pain (e.g., symptomatic osteoarthritis or adhesive capsulitis) presenting to an outpatient orthopedic or rheumatology clinic. After evaluation including history, focused musculoskeletal exam, and review of prior imaging, the clinician determines a targeted intra-articular or soft-tissue corticosteroid injection is appropriate for short-term relief. Consent is obtained and the procedure is performed in the clinic treatment room. Medication administered is J3301 (triamcinolone acetonide 10 mg) via a sterile technique using an appropriate needle and, when indicated, ultrasound guidance. The visit includes documentation of the indication, informed consent, laterality (if applicable), medication name and dose, lot number, route (e.g., intra-articular, periarticular), any associated anesthesia (local anesthetic), and post-procedure instructions. Observation for immediate adverse reaction occurs for several minutes before discharge with return precautions documented.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the day of a procedure | Use when a distinct E/M visit is provided in addition to the injection on the same day. |